

ForPatients

by Roche

Solid Tumors

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Trial Status
Completed

Trial Runs In
6 Countries

Trial Identifier
NCT04642365 2020-003164-82
BP42595

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04642365 2020-003164-82 BP42595
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
